Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$4.49
+4.7%		$11.10
$3.70
▼
$23.00
$18.63M0.0215,120 shs9,110 shs
eXoZymes Inc. stock logo
EXOZ
eXoZymes
$4.00
+2.6%		$6.00
$3.70
▼
$18.40
$37.20M3.196,781 shs5,152 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$1.49
-3.2%		$2.08
$1.09
▼
$2.60
$41.35M0.89491,203 shs110,605 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$3.38
-3.8%		$4.41
$3.29
▼
$20.00
$10.87M1.462,270 shs14,981 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
-12.45%-37.37%-64.56%-64.16%-61.86%
eXoZymes Inc. stock logo
EXOZ
eXoZymes
-0.51%-2.50%-37.00%-17.20%-66.61%
INmune Bio, Inc. stock logo
INMB
INmune Bio
-4.35%-6.67%-28.70%-4.94%-13.48%
Passage Bio, Inc. stock logo
PASG
Passage Bio
-2.23%-2.50%-29.09%-28.95%-57.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
$4.49
+4.7%		$11.10
$3.70
▼
$23.00
$18.63M0.0215,120 shs9,110 shs
eXoZymes Inc. stock logo
EXOZ
eXoZymes
$4.00
+2.6%		$6.00
$3.70
▼
$18.40
$37.20M3.196,781 shs5,152 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$1.49
-3.2%		$2.08
$1.09
▼
$2.60
$41.35M0.89491,203 shs110,605 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$3.38
-3.8%		$4.41
$3.29
▼
$20.00
$10.87M1.462,270 shs14,981 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
-12.45%-37.37%-64.56%-64.16%-61.86%
eXoZymes Inc. stock logo
EXOZ
eXoZymes
-0.51%-2.50%-37.00%-17.20%-66.61%
INmune Bio, Inc. stock logo
INMB
INmune Bio
-4.35%-6.67%-28.70%-4.94%-13.48%
Passage Bio, Inc. stock logo
PASG
Passage Bio
-2.23%-2.50%-29.09%-28.95%-57.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
1.00
SellN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
1.50
ReduceN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.50
Moderate BuyN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.11
Hold$13.25292.59% Upside

Current Analyst Ratings Breakdown

Latest PASG, INMB, EXOZ, and BKHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D)
10/2/2026
eXoZymes Inc. stock logo
EXOZ
eXoZymes
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold
8/26/2026
eXoZymes Inc. stock logo
EXOZ
eXoZymes
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
8/19/2026
INmune Bio, Inc. stock logo
INMB
INmune Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
8/6/2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/5/2026
INmune Bio, Inc. stock logo
INMB
INmune Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
$70K531.43N/AN/A$0.40 per share10.00
INmune Bio, Inc. stock logo
INMB
INmune Bio
$50K826.95N/AN/A$0.88 per share1.69
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$5.90 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
-$9.16M-$1.19N/AN/AN/AN/A-292.15%-158.66%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$45.93M-$0.67N/AN/AN/AN/A-82.87%-62.23%10/29/2026 (Estimated)
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$45.52M-$11.32N/AN/AN/AN/A-218.59%-72.93%11/9/2026 (Estimated)

Latest PASG, INMB, EXOZ, and BKHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$2.43N/AN/AN/AN/AN/A
10/29/2026Q3 2026
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.1467N/AN/AN/A$1.88 millionN/A
10/6/2026Q3 2026
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A$0.26N/A$0.26N/AN/A
8/13/2026Q2 2026
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/A-$0.33N/A-$0.33N/AN/A
8/10/2026Q2 2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$2.44-$2.44N/A-$2.44N/AN/A
8/6/2026Q2 2026
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.2067-$0.05+$0.1567-$0.05$1.16 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/AN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/AN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
0.01
3.81
3.81
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
4.04
4.04
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
1.22
1.22

Institutional Ownership

CompanyInstitutional Ownership
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%

Insider Ownership

CompanyInsider Ownership
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
N/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
58.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
21.40%
Passage Bio, Inc. stock logo
PASG
Passage Bio
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Hawk Acquisition Corporation stock logo
BKHA
Black Hawk Acquisition
24.15 millionN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
329.30 million3.91 millionN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2127.75 million21.82 millionOptionable
Passage Bio, Inc. stock logo
PASG
Passage Bio
1303.22 million3.06 millionNo Data

Recent News About These Companies

PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
October 21 at 3:04 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261021926099/en/pasg-stock-alert-halper-sadeh-llc-is-investigating-whether-passage-bio-inc.-is-obtaining-a-fair-price-for-its-shareholders/
Passage Bio amends merger terms: what it means for Passage Bio stock
October 20 at 10:30 PM  |  ad-hoc-news.deA
$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD
October 20 at 6:42 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3385043/0/en/hareholder-alert-is-it-a-fair-deal-for-you-the-m-a-class-action-firm-is-investigating-the-merger-utz-saft-pasg-and-fnwd.html
Passage Bio, Inc. (PASG) - What Are Investment Firms Saying About This Stock?
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31130684
Passage Bio outlines USD 100.0 million financing for Passage Bio stock
October 16, 2026  |  ad-hoc-news.deA
Passage Bio stock gains 1.01 percent as Remix deal advances
September 24, 2026  |  ad-hoc-news.deA
Passage Bio Amends Remix Merger, Private Financing Terms
September 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/passage-bio-amends-remix-merger-private-financing-terms?utm_source=marketbeat.com&utm_medium=referral
Passage Bio stock reacts to reverse split as investors watch next steps
September 2, 2026  |  ad-hoc-news.deA
Insider Buying: Passage Bio (NASDAQ:PASG) Major Shareholder Purchases 50,055 Shares
June 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pasg-insider-buying-and-selling-2026-06-30/
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
June 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4917592-passage-bio-inc-pasg-m-and-a-call-prepared-remarks-transcript
PASG stock slumps 16% after-hours — what’s driving the selloff?
June 24, 2026  |  msn.comhttps://www.msn.com/en-in/money/top-stocks/pasg-stock-slumps-16-after-hours-what-s-driving-the-selloff/ar-AA26taMY
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/passage-bio-and-remix-therapeutics-announce-merger-agreement-1036273642
Passage Bio and Remix Therapeutics Announce Merger Agreement
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3317152/0/en/passage-bio-and-remix-therapeutics-announce-merger-agreement.html
Passage Bio, Inc. résilie son accord de collaboration de recherche avec Gemma Biotherapeutics, Inc
June 3, 2026  |  zonebourse.comZ
Passage Bio Ends Key Collaborations and Office Lease
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/passage-bio-ends-key-collaborations-and-office-lease?utm_source=marketbeat.com&utm_medium=referral
Passage Bio Shareholders Approve Directors and Executive Pay
May 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/passage-bio-shareholders-approve-directors-and-executive-pay?utm_source=marketbeat.com&utm_medium=referral
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
May 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/passage-bio-inc-pasg-stock-123559923.html
Passage Bio (PASG) price target decreased by 62.83% to 11.63
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/passage-bio-pasg-price-target-decreased-by-6283-to-1163/ar-AA21UGed
TD Cowen downgrades Passage Bio (PASG)
April 23, 2026  |  msn.comhttps://www.msn.com/en-us/money/technology/td-cowen-downgrades-passage-bio-pasg/ar-AA21r898
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276853/0/en/passage-bio-reports-updated-interim-data-from-uplift-d-trial-and-provides-regulatory-and-corporate-updates.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Hawk Acquisition stock logo

Black Hawk Acquisition NASDAQ:BKHA

$4.49 +0.20 (+4.66%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Black Hawk Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2023 and is based in Danville, California.

eXoZymes stock logo

eXoZymes NASDAQ:EXOZ

$4.00 +0.10 (+2.56%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$1.49 -0.05 (-3.25%)
As of 12:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$3.38 -0.14 (-3.85%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas